• English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • English 
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Login
View Item 
  •   University of Thessaly Institutional Repository
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • View Item
  •   University of Thessaly Institutional Repository
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
All of DSpace
  • Communities & Collections
  • By Issue Date
  • Authors
  • Titles
  • Subjects

Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience

Thumbnail
Author
Tillmann, H. L.; Hadem, J.; Leifeld, L.; Zachou, K.; Canbay, A.; Eisenbach, C.; Graziadei, I.; Encke, J.; Schmidt, H.; Vogel, W.; Schneider, A.; Spengler, U.; Gerken, G.; Dalekos, G. N.; Wedemeyer, H.; Manns, M. P.
Date
2006
DOI
10.1111/j.1365-2893.2005.00695.x
Keyword
fulminant hepatitis
hepatitis B
lamivudine
severe acute hepatitis
therapy
ACUTE LIVER-FAILURE
NON-HODGKINS-LYMPHOMA
VIRAL-HEPATITIS
THERAPY
TRANSPLANTATION
VIRUS
INFECTION
REACTIVATION
REINFECTION
OUTBREAK
Gastroenterology & Hepatology
Infectious Diseases
Virology
Metadata display
Abstract
Acute hepatitis B progresses to liver failure with the need of liver transplantation in about 1% of cases. We treated patients with severe acute or fulminant hepatitis B with lamivudine in an attempt to prevent hepatitis B virus (HBV) reinfection after potential liver transplantation. Since September 2000, 17 patients with severe acute or fulminant HBV infection were treated with 100 or 150 mg lamivudine daily once we had evidence for a severe course as indicated by an INR > 2.0. These were compared to a historic control from our unit and to external patients. Fourteen of the 17 patients (82.4%) survived with full recovery without liver transplantation. All these 14 individuals cleared HBsAg on lamivudine within less than 6 months. Twelve patients recovered quickly as indicated by a normalized prothrombin time within 1 week while two patients had a more prolonged course. None of the patients showed an adverse event. Three patients requiring transplantation despite lamivudine therapy had more advanced disease on admission, of whom one had additionally ingested paracetamol (acetaminophen) while the second was already HBV-DNA negative by polymerase chain reaction on admission. The lamivudine treated patients had significant higher frequency of survival without liver transplantation 82.4 vs 20% (4/20) in the historic control (P < 0.001). Similar data were derived from external centres using lamivudine (15/20, 75%). Lamivudine is safe in patients with severe acute or fulminant hepatitis B, leading to fast recovery with the potential to prevent liver failure and liver transplantation when administered early enough.
URI
http://hdl.handle.net/11615/33665
Collections
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ. [9728]

Related items

Showing items related by title, author, creator and subject.

  • Thumbnail

    Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta 

    Kabaçam, G.; Wedemeyer, H.; Savaş, B.; Keskin, O.; Dalekos, G.; Tabak, F.; Idilman, R.; Erhardt, A.; Yalçin, K.; Bozdayi, M. A.; Bozkaya, H.; Manns, M.; Dienes, H.; Yurdaydin, C.; Berg, T.; Böcher, W.; Bohle, H.; Buggisch, P.; Cornberg, M.; Ers̈oz, G.; Feyerabend, S.; Hinrichsen, H.; Manok, M.; Häussinger, D.; Herzog, W.; Hofmann, W. P.; Plein, K.; Hardt, H.; Porst, H.; Mederacke, I.; Rigopoulou, E. I.; Sentürk, H.; Wagner, E. K. V. (2014)
    Background & Aims: Immunohistochemical assessment of liver tissue in chronic delta hepatitis (CDH) is underinvestigated. Aim of the study was (i) to assess variables associated with hepatitis D antigen (HDAg), hepatitis B ...
  • Thumbnail

    Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases 

    Georgiadou, S. P.; Zachou, K.; Rigopoulou, E.; Liaskos, C.; Mina, P.; Gerovasilis, F.; Makri, E.; Dalekos, G. N. (2004)
    Occult hepatitis B virus (HBV) infection has been reported in patients with chronic hepatitis C who are negative for HBV surface antigen (HBsAg). However, the significance of 'silent' HBV in hepatitis C virus (HCV) infection ...
  • Thumbnail

    Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse non-viral hepatic diseases 

    Georgiadou, S. P.; Zachou, K.; Rigopoulou, E.; Liaskos, C.; Mina, P.; Gerovasilis, F.; Makri, E.; Dalekos, G. N. (2004)
Η δικτυακή πύλη της Ευρωπαϊκής Ένωσης
Ψηφιακή Ελλάδα
ΕΣΠΑ 2007-2013
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister (MyDspace)
Help Contact
DepositionAboutHelpContact Us
Choose LanguageAll of DSpace
EnglishΕλληνικά
Η δικτυακή πύλη της Ευρωπαϊκής Ένωσης
Ψηφιακή Ελλάδα
ΕΣΠΑ 2007-2013